Abstract:The HIV-1 CA protein has gained remarkable attention as a promising therapeutic target for the development of new antivirals, due to its pivotal roles in HIV-1 replication (structural and regulatory). Herein, we report the design and synthesis of three series of benzenesulfonamide-containing phenylalanine derivatives obtained by further structural modifications of PF-74 to aid in the discovery of more potent and drug-like HIV-1 CA inhibitors. Structure-activity relationship studies of these compounds led to the identification of new phenylalanine derivatives with a piperazinone moiety, represented by compound 11l, which exhibited anti-HIV-1(NL4-3) activity 5.78-fold better than PF-74. Interestingly, 11l also showed anti-HIV-2(ROD) activity (EC50 = 31 nM), with almost 120 times increased potency over PF-74. However, due to the higher significance of HIV-1 as compared to HIV-2 for the human population, this manuscript focuses on the mechanism of action of our compounds in the context of HIV-1. SPR studies on representative compounds confirmed CA as the binding target. The action stage determination assay demonstrated that these inhibitors exhibited antiviral activities with a dual-stage inhibition profile. The early-stage inhibitory activity of compound 11l was 6.25 times more potent as compared to PF-74 but appeared to work via the accelerating capsid core assembly rather than stabilization. However, the mechanism by which they exert their antiviral activity in the late stage appears to be the same as PF-74 with less infectious HIV-1 virions produced in their presence, as judged p24 content studies. MD simulations provided the key rationale for the promising antiviral potency of 11l. Additionally, 11l exhibited a modest increase in HLM and human plasma metabolic stabilities as compared to PF-74, as well as a moderately improved pharmacokinetic profile, favorable oral bioavailability, and no acute toxicity. These studies provide insights and serve as a starting point for subsequent medicinal chemistry efforts in optimizing these promising HIV inhibitors.

Design, Synthesis, and Mechanistic Study of 2-Piperazineone-bearing Peptidomimetics As Novel HIV Capsid Modulators

Discovery and Mechanistic Investigation of Piperazinone Phenylalanine Derivatives with Terminal Indole or Benzene Ring as Novel HIV-1 Capsid Modulators

Design, Synthesis, and Mechanism Study of Dimerized Phenylalanine Derivatives As Novel HIV-1 Capsid Inhibitors.

Design, Synthesis, and Mechanistic Study of 2-Pyridone-bearing Phenylalanine Derivatives As Novel HIV Capsid Modulators

Design, Synthesis and Structure—Activity Relationships of Phenylalanine-Containing Peptidomimetics As Novel HIV-1 Capsid Binders Based on Ugi Four-Component Reaction

Discovery of Novel 1,4-Disubstituted 1,2,3-Triazole Phenylalanine Derivatives As HIV-1 Capsid Inhibitors

From Design to Biological Mechanism Evaluation of Phenylalanine-Bearing HIV-1 Capsid Inhibitors Targeting a Vital Assembly Interface

Discovery, Crystallographic Studies, and Mechanistic Investigations of Novel Phenylalanine Derivatives Bearing a Quinazolin-4-one Scaffold as Potent HIV Capsid Modulators

The discovery and design of novel HIV-1 capsid modulators and future perspectives.

Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors

Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitors

Design, Synthesis, and Biological Evaluation of Novel 2-Methylpiperazine Derivatives As Potent CCR5 Antagonists.

Design, Synthesis and Structure-Activity Relationships of 4-Phenyl-1h-1,2,3-triazole Phenylalanine Derivatives As Novel HIV-1 Capsid Inhibitors with Promising Antiviral Activities.

Quinazolinone-based subchemotypes for targeting HIV-1 capsid protein: design and synthesis

Design, Synthesis and Biological Evaluation of Novel Piperazine Derivatives As CCR5 Antagonists

Design, Synthesis, and Mechanistic Investigations of Phenylalanine Derivatives Containing a Benzothiazole Moiety As HIV-1 Capsid Inhibitors with Improved Metabolic Stability

Design, Synthesis and Biological Activity of Bicyclic Piperidine-Based HIV-1 Inhibitors

Design, Synthesis, and Biological Evaluation of Novel Piperidine-4-carboxamide Derivatives As Potent CCR5 Inhibitors

Design, synthesis and biological evaluation of protease inhibitors containing morpholine cores with remarkable potency against both HIV-1 subtypes B and C

"Pseudosubstrate Envelope"/Free Energy Perturbation-Guided Design and Mechanistic Investigations of Benzothiazole HIV Capsid Modulators with High Ligand Efficiency

An Insight on Medicinal Aspects of Novel HIV-1 Capsid Protein Inhibitors